Chutes & Ladders—Cerevel CEO to exit as company nears inflection point

05 May 2023
www.fiercebiotech.com
Executive ChangeAcquisitionPhase 2IPO
None
Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.
After 4-year run, Cerevel CEO set to step down
Cerevel Therapeutics
Cerevel CEO Tony Coles, M.D., will be handing over the reins to Bain Capital’s Ron Renaud on June 12. Renaud, who is Coles’ longtime friend, will become the neuroscience biotech’s new president, CEO and board member, while Coles will maintain his role as chair.
Cerevel Therapeuticsta-entity-type="media" data-entity-uuid="4594572c-6bd9-4cd1-b936-f44546db0e23" data-view-mode="thumbnail"/>
Cerevelook on the head role of the Pfizer spinout back in 2019, Bain Capitalvel’s public market debut in 2020 and overseeing pipeline development of several neurological diseases, such as Parkinson’s, epilepsy and schizophrenia.
Renaud, a current partner at Bain Capital—which has invested heavily in Cerevel—comes in at a critical inflection point. The company anticipates seven data readouts in the next 12 to 18 months, pinning hopes specifically on emraclidine, which is currently being evaluated in a phase 2 trial in patients with schizophrenia who experience psychosis. Renaud said Cerevel is planning for a commercial launch of the asset.
Colesenaud" data-entity-type="mediaPfizer-entity-uuid="7682f257-d923-44ac-9e5d-9e6bd778d512" data-view-mode="thumbnail"/>neurological diseasesschizophrenia
The incoming CEO has held theBain Capitaltwo biotechs over the last few Cerevel. He led mRNA-based Translate Bio for seven years until late 2021, when the company was acquired by Sanofi for $3.2 billion. Before that, he servemraclidinedent and CEO of Idenix Pharmaceuticals, which was acquired by Merck & Co.schizophreniallion in 2014. Tpsychosisive has also sCerevels chair of several biotechs such as Atara Biotherapeutics, Ikena Oncology and Axial Biotherapeutics, among others. Fierce Biotech
Day One revamps C-suite
Day One’s co-founder and chief medical officer, Samuel Blackman, M.D., Ph.D., has been with the company, since, well, day one. And while he’s sticking around, he’s moving outside of the executive team to head research and development for the company, guiding earlier scientific research. He’d been Day One’s CMO since November 2022.
He’ll be replaced by Raphaël Rousseau, M.D., Ph.D., who recently served as chief medical officer at Neogene Therapeutics and Gritstone Bio. Before leading clinical development at biotechs, Rousseau was the pediatric franchise head at Genentech, creating the innovative pediatric drug development team which in part incorporated kids into all stages of the development process for new oncology treatments.
In addition to revamping R&D leadership, Day One has named Lauren Merendino as chief commercial officer. She’s a fellow Genentech alum herself, having previously been the VP of neurological rare diseases before becoming commercial chief at Myovant Sciences. Release
Former Iovance CEO and VC partner jumps to LassenNeogene TherapeuticsGritstone BioGenentech
Maria FIovancePh.D., evidently couldn’t resLassene opportunity to return to a biotech C-suite, being named CEO of Lassen Therapeutics. She’d spent less than two years as a venture partner at Frazier Life Sciences after leading Iovance Biotherapeutics for more than five years.
Lassen Therapeuticshe helped grow the company’s market cap twentyfold, from $200 million to $4 billion, by growing the company’s pipeline of tumor-infiltrating lymphocytes. The company now has more than a half-dozen treatment combos in mid- to late-stage trials, including two ongoing pivotal trials for its lead asset, lifileucel.
She’s also had experience developing breakthrough therapies that have caught the eye of Big Pharma, namely ImbruviLassen Therapeuticsardis was chief of oncology operations and alliances at Pharmacyclics where she managed the paIovance Biotherapeuticsiotech and Janssen, which licensed what ultimately became Imbruvica. She then moved to Acerta where she oversaw the clinical development program for acalabrutinib (now Calquence) and was part of the team that conducted due diligence ahead of AstraZeneca’s $4 billion stake in the company. Release
> FoundinIovancedent and CEO of AvroBio Geoff MacKay is leaving to join an early-stage venture, the company announced this week. MacKay has ltumore company for the last eight years and will be replaced on an interim basis by current CFO Erik Ostrowski. Releaselifileucel
> Women’s health-focused ObsEva has landed on a new CEO, naming Fabien de Ladonchamps for the job. He’s been a member of the company’s executive team fooncology 10 years, having previously Pharmacyclicsef administrative officer and interim CFO. ReleaseJanssenImbruvicaAcertaacalabrutinibCalquenceAstraZeneca
> After co-founder and CEO MasouAvroBiooie, M.D., Ph.D, recently stepped down, Inspirna has named a new leader, calling on Usman “Oz” Azam, M.D., to take the chief executive reins. Azam was previously head of cell and gene therapies at Novartis before taking CEO roles at Empyrean Neuroscience and Tmunity. Release
> Ariella Kelman, M.D., iObsEvang into the C-suite at Biora Therapeutics, accepting the chief medical officer job. She most recently was SVP of clinical development at HI-Bio after more than 15 years at Genentech. Release
> Kazia Therapeutics’ CEO and managing director James Garner has resigned afterInspirnaan seven years helming the oncology biotech. Kazia’s chief medical officer John Friend, M.D., has immediately assumed the role as CEO. ReleaseNovartisEmpyrean NeuroscienceTmunity
> The Daily Wire co-founder Ben Shapiro has joined OraBiora Therapeuticss’ board. Shapiro beneficially owns more than 4% of the company’s outstanding stock, making him HI-Bioificant shareholder. ReleaseGenentech
> Kazia Therapeuticsutics has tapped Novartis’ Clifford Brass, M.D., Ph.D., to serve as chief medical officer. Clifford had been witKazia Pharma Novartis since 2011, most recently working as VP and head of clinical sciences for hepatology, gastroenterology and transplantation. Release
> Vera Therapeutics has tapped Kerry Cooper, M.D., Oramed Pharmaceuticalsical affairs. Cooper joins Vera from ProKidney and has held leadership roles at AstraZeneca and Amgen in the past. Release
> Resolution Therapeuticsis shaking uNovartisnior management team with one departure and two promotions. At the end of June, longtime EVP of Business Development Marco Caremi will retire, while Director of Business Development Laura Faravelli will be promoted to VP of business development and VP of Finance Roberto Galli will become chief financial officer. Release
> Vera Therapeuticss has circled up a new VP of drug discovery. Monika Ermann, Ph.D., is joining the company fProKidneyentia, where she was director of cAstraZenecalogy.Amgenase
> Newron Pharmaceuticals chief scientific officer Ian Churcher is taking on the new role of chief technology officer, while Louise Modis, Ph.D., is stepping into the CSO role. Modis joins from Mogrify and has experience across GSK, Boehringer Ingelheim and Millennium Pharmaceuticals. Release
> Curve Therapeuticsd Bryn Pharma has expanded with the addition of three new executives: Nurry Hong as chief straExscientiausiness development officer, Steve Killmeyer as chief financial officer and Lisa Lucifero as VP and head of human resources. Most recently, Hong served as CEO of Pareto Bio, Killmeyer was head of finance and strategy for Nestle Health Science’s Aimmune Therapeutics and Lucifero was head of HR for DBV Technologies’ U.S. and Australian arms. Release
> Amphista Therapeuticsing Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer. Englese joins from Aziyo Biologics, where he was also CCO, while LesMogrifyins from Park Therapeutics,GSKerBoehringer IngelheimopmenMillennium PharmaceuticalsRelease
> Anaphylaxisnu, Ph.D.Bryn Pharmaed as chief scientific officer at Unikum Therapeutics. The scientist has previously worked at ElevateBio and bluebird bio. ReleasePareto BioNestle Health ScienceAimmune TherapeuticsDBV Technologies
> Tris Pharmasby, Ph.D., has left Oxford Biomedical after eight years, joining medical research charity LifeArc as chief business officer. ReleaAziyo BiologicsPark Therapeutics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.